CD38 and neoplasm: We thus believe these findings support the notion that alterations in surface proteins found after mAb treatment on patent tumors, such as increases in CD55 and CD59,5 are caused by other therapy-induced selective pressure within the tumor microenvironment, not CD38 loss.